軍團菌檢測試劑盒（免疫捕獲法）

廣州健侖生物科技有限公司

主要用途：用于檢測尿樣中嗜肺軍團菌血清型1抗原，以支持軍團菌感染的診斷。

產品規格：20T/盒

存儲條件：2-30℃

軍團菌檢測試劑盒（免疫捕獲法）

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

【產品介紹】

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-3室
【企業文化】

經過反復試驗，研究人員zui終發現了這第二個基因，即存在于大腦中的特殊tRNAs中的GTPBP2——tRNAs的作用是幫助DNA翻譯成蛋白。這種tRNA基因的突變會引起核糖體停止在一個特殊的DNA序列上，減慢蛋白合成過程。
研究人員指出，由于這項研究采用的遺傳背景是用于構建其他人類疾病模型，因此采用這種小鼠模型的研究人員也要多加注意。
杜克大學醫學院的科學家在HIV感染的人中發現，產生廣譜中和抗體的一種免疫機制。這項研究結果在很大程度上是HIV疫苗誘導產生有效的中和抗體的關鍵。相關文章發表于2014年7月24日的《Cell》雜志上。該研究小組發現，兩種不同的B細胞譜系抗體聯手，刺激備受追捧的廣譜中和抗體對抗HIV。該研究組由杜克大學艾滋病毒/艾滋病疫苗免疫學，免疫原發現(CHAVI-ID)中心杜克大學人類疫苗研究所的主任巴頓·海恩斯，以及該疫苗研究中心的國家過敏和傳染病研究所(NIAID)的主任John Mascola醫學博士所的。
海恩斯說，這些可中和多種hiv病毒株的抗體的激活是是一個性疫苗的關鍵策略。高水平的這種抗體在約20%的艾滋病毒感染者中產生。
去年，該研究組在Nature雜志上*描述廣譜中和抗體(bnAbs)的共同進化，以及病毒激活感染者內的這些抗體。現在，同樣的研究小組報告了患者體內的免疫系統的B細胞學會中和許多種HIV病毒株的確切機制。
在這項新研究中，科學家驚訝地發現，一個輔助的中和抗體組和交叉反應中和抗體合作，產生一套強而有力的廣譜中和抗體。其他輔助譜系包含與導致感染的病毒中和的抗體。

這種抗體靶向病毒的外膜區域，該區域也能夠與廣譜中和抗體結合。在這樣做時，輔助譜系抗體選擇具有較強能力的病毒刺激廣譜中和抗體系。
因此，一組抗體選擇一組病毒逃逸突變體“教導”廣譜中和抗體系如何中和HIV變種?？茖W家推測，這個過程會反復發生在整個感染中，導致中和多種HIV毒株的抗體譜的產生。
“一個bnAb譜系的成熟可以通過輔助譜系來提升的這一發現，對艾滋病疫苗的發展有著重要的影響，”文章*作者、杜克大學人類疫苗研究所Feng Gao博士說。“來自于初始傳播/原始病毒的免疫原的反復免疫，以及逃避變體與bnAb譜系具有更高的結合能力，都可能需要激活bnAbs。”
“下一步是要在能夠產生廣譜中和抗體的其他個體中進行類似的研究，并確定誘導這種抗體的其他特異性是一個普遍的機制，” 海恩斯說。“然后，zui終證明，這一發現可用于設計可誘導廣譜中和抗體的免疫原。”
利用這項研究的結果，該研究模仿自然感染艾滋病毒的光譜中和抗體發展，已經設計出一種疫苗免疫原，有選擇性地觸發產生抗體的B細胞進行合作，產生廣譜中和抗體。
隨著癌癥的發育，正常的血液供給慢慢不能滿足其需求，因此過度生長的腫瘤組織吸收的氧氣量就會比正常組織少，這種低氧環境稱之為缺氧狀態，缺氧狀態往往和不同類型的惡性腫瘤的發生相關。
這項研究中研究人員利用結腸癌組織進行研究發現，缺氧條件可以誘發關鍵的腫瘤抑制基因MLH1發生沉默;與此同時研究人員也發現了一種名為LSD1的酶類，這種酶是一種賴氨酸特殊的脫甲基酶，酶類LSD1連同MLH1都可以作為逆轉或者阻斷沉默過程的靶點;由于LSD1是一種特殊酶類，因此科學家們可以利用小分子對其產生的靶向作用來抑制其活性。

After trial and error, the researchers finally discovered the second gene, the role of GTPBP2 - tRNAs in specific tRNAs found in the brain, to help translate DNA into proteins. This tRNA gene mutation causes the ribosome to stop on a particular DNA sequence, slowing the protein synthesis process.
Researchers noted that as the genetic background used in this study was to build other human disease models, researchers using this mouse model should pay more attention.
Scientists at Duke University School of Medicine found in HIV-infected humans an immune mechanism that produces broad-spectrum neutralizing antibodies. The results of this study are to a large extent the key to the generation of effective neutralizing antibodies by HIV vaccines. The article appeared in the July 24, 2014 "Cell" magazine. The team found that two different B-cell lineage antibodies work in tandem to stimulate the highly sought-after broad-spectrum neutralizing antibodies against HIV. The research team was led by Barton Haynes, director of the Duke University HIV Vaccine Immunology, Duke University Center for Human Immunization Discovery (CHAVI-ID) Center at Duke University, and the National Allergy and Infectious Diseases Led by John Mascola, MD, director of the Institute (NIAID).
Haynes said the activation of antibodies that neutralize multiple hiv strains is a key strategy for a global vaccine. High levels of this antibody are produced in about 20% of HIV-infected individuals.
Last year, the team first described in Nature the co-evolution of broad-spectrum neutralizing antibodies (bnAbs), and the virus activates these antibodies in infected individuals. The same team now reports on the exact mechanism by which B cells in the immune system in a patient learn to neutralize many of the HIV strains.
In this new study, scientists were surprised to find that a co-neutralizing antibody group works with cross-reacting neutralizing antibodies to produce a robust set of broad-spectrum neutralizing antibodies. Other accessory lineages contain antibodies that neutralize the virus that causes the infection.

This antibody targets the outer membrane region of the virus, which is also capable of binding to a broad spectrum of neutralizing antibodies. In doing so, the accessory lineage antibody selects a more competent virus to stimulate the broad-spectrum neutralizing antibody system.
Thus, a panel of antibodies selected from a group of virus escape mutants "teaches" how broad-spectrum neutralizing antigens neutralize HIV variants. Scientists speculate that this process occurs repeatedly throughout the infection, resulting in the production of antibody profiles that neutralize multiple HIV strains.
"The discovery that the maturation of a bnAb lineage can be enhanced by ancillary lineages has a significant impact on the development of an AIDS vaccine," said lead author Feng Gao, PhD, of Duke University's Human Vaccine Institute. "Repeated immunizations from immunogens that originate / originate the virus, and the ability of escape variants to bind to the bnAb lineage, may require the activation of bnAbs."
"The next step is to do similar research in other individuals that are capable of producing broad-spectrum neutralizing antibodies and to establish that other specificities that induce such antibodies are a common mechanism," Haines said. "And then it turns out that this finding can be used to design immunogens that induce broad-spectrum neutralizing antibodies."
Using the results of this study, which mimicked the development of neutralizing antibodies in naturally infected HIV, a vaccine immunogen has been designed that selectively triggers the production of antibody-producing B cells to produce broad-spectrum neutralizing antibodies.
With the development of cancer, the normal blood supply slowly can not meet their needs, so excessive growth of tumor tissue to absorb oxygen than the normal tissue less, this hypoxic environment called hypoxia, hypoxia often And different types of malignancies related to the occurrence.
In this study, researchers using colon cancer tissue research found that hypoxia can induce key tumor suppressor gene MLH1 silence; at the same time researchers also found a class called LSD1 enzymes, this enzyme is a Species of lysine-specific demethylase, enzymes LSD1 together with MLH1 can be used as reversing or blocking the process of silencing the target; because LSD1 is a special enzyme, so scientists can make use of small molecules on their target To act to inhibit its activity.